Search

Your search keyword '"Geoffrois, L"' showing total 381 results
Start Over Author "Geoffrois, L"
381 results on '"Geoffrois, L"'

2. Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial

Author

Pignot, G., Fendler, J.P., Guy, L., Verhoest, G., Mottet, N., Doerfler, A., Abadie-Lacourtoisie, S., Azzouzi, A., Mongiat, P., Geoffrois, L., Eschwege, P., Di Fiore, F., Roubaud, G., Hoepffner, J.L., Barthelemy, P., Lang, H., Voog, E., Mandron, E., Tourani, J.M., Serrrate, C., Colau, A., Saldana, C., de La Taille, A., Nguyen, T., Kleinclauss, F., Loriot, Y., Irani, J., Eymard, J.C., Larre, S., Huillard, O., Zerbib, M., Rolland, F., Rigaud, J., Houede, N., Droupy, S., Malouf, G., Roupret, M., Vieillot, S., Letang, N., Lharidon, T., Gaschignard, N., Hilgers, W., Davin, J.L., Groeneveld, C.S., Pfister, C., Culine, S., Harter, V., Krucker, C., Fontugne, J., Dixon, V., Sirab, N., Bernard-Pierrot, I., de Reyniès, A., Radvanyi, F., and Allory, Y.

Published
2024
Full Text
View/download PDF

3. Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma: Oncological outcomes and predictive factors of surgical difficulties

Author

Pignot, G., primary, Margue, G., additional, Bigot, P., additional, Lang, H., additional, Balssa, L., additional, Roubaud, G., additional, Borchiellini, D., additional, Bensalah, K., additional, Schlürmann, F., additional, Ladoire, S., additional, Parier, B., additional, Bernhard, J.C., additional, Cassuto, O., additional, Albiges, L., additional, Thibault, C., additional, Ingels, A., additional, Cherifi, F., additional, Waeckel, T., additional, Walz, J., additional, Flippot, R., additional, Geoffrois, L., additional, Gravis, G., additional, and Barthelemy, P., additional

Published
2024
Full Text
View/download PDF

4. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases

Author

Albert, S., Andry, G., Babin, E., Bach, C., Badet, J.-M., Badoual, C., Baglin, A.C., Banal, A., Barry, B., Baudin, E., Baujat, B., Bensadoun, R.J., Bertolus, C., Bessède, J.-P., Blanchard, D., Borel, C., Bozorg-Grayeli, A., Breheret, R., Breton, P., Brugel, L., Calais, G., Casiraghi, O., Cassagnau, E., Castillo, L., Ceruse, P., Chabolle, F., Chevalier, D., Chobaut, J.C., Choussy, O., Cosmidis, A., Coste, A., Costes, V., Crampette, L., Darrouzet, V., Demez, P., Dessi, P., Devauchelle, B., Dolivet, G., Dubrulle, F., Duflo, S., Dufour, X., Faivre, S., Fakhry, N., Ferron, C., Floret, F., de Gabory, L., Garrel, R., Geoffrois, L., Gilain, L., Giovanni, A., Girod, A., Guerrier, B., Hans, S., Herman, P., Hofman, P., Housset, M., Jankowski, R., Jegoux, F., Juliéron, M., Kaminsky, M.-C., Kolb, F., St Guily, J. Lacau, Laccoureye, L., Lallemant, B., Lang, P., Lartigau, E., Lavieille, J.-P., Lefevre, M., Leroy, X., Malard, O., Massip, F., Mauvais, O., Merol, J.-C., Michel, J., Mom, T., Morinière, S., de Monès, E., Moulin, G., Noel, G., Poissonnet, G., Prades, J.-M., Radulesco, T., de Raucourt, D., Reyt, E., Righini, C., Robin, Y. Marie, Rolland, F., Ruhin, B., Sarroul, N., Schultz, P., Serrano, E., Sterkers, O., Strunski, V., Sudaka, A., Tassart, M., Testelin, S., Thariat, J., Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbeele, T., Varoquaux, A., Veillon, F., Vergez, S., Wassef, M., Dahan, Laurie Saloner, Giorgi, Roch, Vergez, Sébastien, Le Taillandier de Gabory, Ludovic, Costes-Martineau, Valérie, Herman, Philippe, Poissonnet, Gilles, Mauvais, Olivier, Malard, Olivier, Garrel, Renaud, Uro-Coste, Emmanuelle, Barry, Béatrix, Bach, Christine, Chevalier, Dominique, Mouawad, Francois, Merol, Jean-Claude, Bastit, Vianney, Thariat, Juliette, Gilain, Laurent, Dufour, Xavier, Righini, Christian-Adrien, Moya-Plana, Antoine, Even, Caroline, Radulesco, Thomas, Michel, Justin, Baujat, Bertrand, and Fakhry, Nicolas

Published
2021
Full Text
View/download PDF

5. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Author

Cohen, EEW, Licitra, LF, Burtness, B, Fayette, J, Gauler, T, Clement, PM, Grau, JJ, del Campo, JM, Mailliez, A, Haddad, RI, Vermorken, JB, Tahara, M, Guigay, J, Geoffrois, L, Merlano, MC, Dupuis, N, Krämer, N, Cong, XJ, Gibson, N, Solca, F, Ehrnrooth, E, and Machiels, J-PH

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Dental/Oral and Craniofacial Disease, Rare Diseases, Cancer, Clinical Research, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Administration, Intravenous, Administration, Oral, Afatinib, Antimetabolites, Antineoplastic, Biomarkers, Tumor, Biopsy, Carcinoma, Squamous Cell, Disease-Free Survival, Head and Neck Neoplasms, Humans, Methotrexate, Neoplasm Metastasis, Neoplasm Recurrence, Local, Predictive Value of Tests, Quinazolines, Squamous Cell Carcinoma of Head and Neck, afatinib, methotrexate, HNSCC, biomarker, phase III, EGFR, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundIn the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Here, we evaluated association of prespecified biomarkers with efficacy outcomes in LUX-H&N1.Patients and methodsRandomized patients with R/M HNSCC and progression following ≥2 cycles of platinum therapy received afatinib (40 mg/day) or methotrexate (40 mg/m2/week). Tumor/serum samples were collected at study entry for patients who volunteered for inclusion in biomarker analyses. Tumor biomarkers, including p16 (prespecified subgroup; all tumor subsites), EGFR, HER2, HER3, c-MET and PTEN, were assessed using tissue microarray cores and slides; serum protein was evaluated using the VeriStrat® test. Biomarkers were correlated with efficacy outcomes.ResultsOf 483 randomized patients, 326 (67%) were included in the biomarker analyses; baseline characteristics were consistent with the overall study population. Median PFS favored afatinib over methotrexate in patients with p16-negative [2.7 versus 1.6 months; HR 0.70 (95% CI 0.50-0.97)], EGFR-amplified [2.8 versus 1.5 months; HR 0.53 (0.33-0.85)], HER3-low [2.8 versus 1.8 months; HR 0.57 (0.37-0.88)], and PTEN-high [1.6 versus 1.4 months; HR 0.55 (0.29-1.05)] tumors. Afatinib also improved PFS in combined subsets of patients with p16-negative and EGFR-amplified tumors [2.7 versus 1.5 months; HR 0.47 (0.28-0.80)], and patients with p16-negative tumors who were EGFR therapy-naïve [4.0 versus 2.4 months; HR 0.55 (0.31-0.98)]. PFS was improved in afatinib-treated patients who were VeriStrat 'Good' versus 'Poor' [2.7 versus 1.5 months; HR 0.71 (0.49-0.94)], but no treatment interaction was observed. Afatinib improved tumor response versus methotrexate in all subsets analyzed except for those with p16-positive disease (n = 35).ConclusionsSubgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high). Future studies are warranted to validate these findings.Clinical trial registrationNCT01345682.

Published
2017

7. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

Author

Loriot, Y., Pagliaro, L., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C., Delva, R., Rolland, F., Theodore, C., Roubaud, G., Gravis, G., Eymard, J.C., Malhaire, J.P., Linassier, C., Habibian, M., Martin, A.L., Journeau, F., Reckova, M., Logothetis, C., Laplanche, A., Le Teuff, G., Culine, S., and Fizazi, K.

Published
2017
Full Text
View/download PDF

10. PRAISE : décrire les effets immunologiques secondaires à l’immunothérapie dans le cancer – analyse de la qualité de vie

Author

Gottenberg, J.E., primary, Cloarec, N., additional, Monnet, I., additional, Najem, A., additional, Rajpar, S., additional, San, T., additional, Porneuf, M., additional, Barthelemy, P., additional, Rizzo, C., additional, Meunier, J., additional, Chauvenet, L., additional, Darut-Jouve, A., additional, Falkowski, S., additional, Paitel, J.F., additional, Geoffrois, L., additional, Litrowski, N., additional, Canellas, A., additional, Dixmier, A., additional, Pracht, M., additional, Martinez, S., additional, Debieuvre, D., additional, Oudard, S., additional, Le Foll, C., additional, Lallier, J., additional, Auberger, B., additional, Kaphan, R., additional, Meniai, F., additional, Lai-Tiong, F., additional, Braithwaite, B., additional, Hamamouche, N., additional, and Servy, H., additional

Published
2022
Full Text
View/download PDF

11. Résultats intermédiaires sur les 658 premiers patients de l’étude PRAISE (Patient-Reported AutoImmunity SEcondary to cancer immunotherapy) : étude de cohorte prospective multicentrique pour le suivi des manifestations auto-immunes sous immunothérapie

Author

Sebbag, E., primary, Cloarec, N., additional, Monnet, I., additional, Najem, A., additional, Rajpar, S., additional, San, T., additional, Porneuf, M., additional, Barthelemy, P., additional, Rizzo, C., additional, Meunier, J., additional, Chauvenet, L., additional, Darut-Jouve, A., additional, Falkowski, S., additional, Paitel, J.F., additional, Geoffrois, L., additional, Litrowski, N., additional, Cannelas, A., additional, Dixmier, A., additional, Pracht, M., additional, Martinez, S., additional, Debieuvre, D., additional, Oudard, S., additional, Le Foll, C., additional, Lallier, J., additional, Auberger, B., additional, Kaphan, R., additional, Meniai, F., additional, Lai-Tiong, F., additional, Cadranel, J., additional, Weiss, L., additional, Nancey, S., additional, Aparicio, T., additional, Chouaid, C., additional, Hamamouche, N., additional, Servy, H., additional, Desjeux, G., additional, Arnold, C., additional, Sauleau, E., additional, Sedmak, N., additional, and Gottenberg, J.E., additional

Published
2022
Full Text
View/download PDF

12. La pandémie COVID-19 est associée à des mélanomes diagnostiqués à un stade plus avancé

Author

Skowron, F., primary, Mouret, S., additional, Seigneurin, A., additional, Montaudié, H., additional, Maubec, E., additional, Grange, F., additional, Quéreux, G., additional, Celerier, P., additional, Adle, A., additional, Dalac, S., additional, De Quatrebarbes, J., additional, Zehou, O., additional, Safia, A., additional, Muller, P., additional, Modiano, P., additional, Misery, L., additional, Litrowski, N., additional, Brunet Possenti, F., additional, Mortier, L., additional, Bens, G., additional, Hervieu, A., additional, Leduc, N., additional, Jouary, T., additional, Lesage, C., additional, Beneton, N., additional, Le Corre, Y., additional, Geoffrois, L., additional, Thomas-Beaulieu, D., additional, Khammari, A., additional, Wierzbicka-Hainaut, E., additional, and Leccia, M.T., additional

Published
2022
Full Text
View/download PDF

14. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial

Author

Colomba, E., primary, Carril Ajuria, L., additional, Dalban, C., additional, Derosa, L., additional, Alves Costa Silva, C., additional, Rassy, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis Mescam, G., additional, Oudard, S., additional, Laguerre, B., additional, Barthelemy, P., additional, Gross Goupil, M., additional, Geoffrois, L., additional, Thiery-Vuillemin, A., additional, Joly Lobbedez, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2022
Full Text
View/download PDF

15. 653O Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter randomized phase II trial

Author

Mirghani, H., primary, Even, C., additional, Larive, A., additional, Pere, H., additional, Fayette, J., additional, Geoffrois, L., additional, Clatot, F., additional, Calderon, B., additional, Tao, Y., additional, Nguyen, T.V.F., additional, Fabiano, E., additional, Kreps, S., additional, Veyer, D., additional, Puech, J., additional, Badoual, C., additional, Garic, F., additional, Auperin, A., additional, and Blanchard, P., additional

Published
2022
Full Text
View/download PDF

16. 1627TiP Impact of patient education on immune-related adverse events (irAEs) during immune checkpoint inhibitor (ICI)

Author

Berger, V.A., primary, Jubé, C., additional, Forestier, A., additional, Mitonneau, C., additional, Humeau, H., additional, Limouzin, S., additional, Tiercin, M., additional, Morlière, L., additional, Geoffrois, L., additional, Cabart, M., additional, Bertholet, M., additional, Llambrich-Molines, C., additional, Breysse, S., additional, Laghouati, S., additional, and Beaumont, N., additional

Published
2022
Full Text
View/download PDF

17. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study

Author

Selle, F., Wittnebel, S., Biron, P., Gravis, G., Roubaud, G., Bui, B.N., Delva, R., Bay, J.O., Fléchon, A., Geoffrois, L., Caty, A., Soares, D.G., de Revel, T., Fizazi, K., Gligorov, J., Micléa, J.M., Dubot, C., Provent, S., Temby, I., Gaulet, M., Horn, E., Brindel, I., and Lotz, J.P.

Published
2014
Full Text
View/download PDF

24. 670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)

Author

Gross-Goupil, M., primary, Fléchon, A., additional, Mourey, L., additional, Topart, D., additional, Gravis, G., additional, Oudard, S.M., additional, Tourani, J-M., additional, Geoffrois, L., additional, Meriaux, E., additional, Thiery-Vuillemin, A., additional, Barthelemy, P., additional, Ladoire, S., additional, Laguerre, B., additional, Zara, L., additional, Perrot, V., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

25. 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)

Author

Alves Costa Silva, C., primary, Derosa, L., additional, Dalban, C., additional, Colomba, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis, G., additional, Oudard, S.M., additional, Laguerre, B., additional, Barthelemy, P., additional, Borchiellini, D., additional, Gross-Goupil, M., additional, Geoffrois, L., additional, Rolland, F., additional, Thiery-Vuillemin, A., additional, Joly, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

26. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

Author

Derosa, L., primary, Alves Costa Silva, C., additional, Dalban, C., additional, Colomba, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis, G., additional, Oudard, S.M., additional, Laguerre, B., additional, Barthelemy, P., additional, Borchiellini, D., additional, Gross-Goupil, M., additional, Geoffrois, L., additional, Rolland, F., additional, Thiery-Vuillemin, A., additional, Joly, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

27. CN54 Impact of the app-based and nurse-led supportive care program AKO@dom on dose-intensity of oral targeted therapies in patients with metastatic renal cell cancer: A multicentric observational retrospective study

Author

Gaillard, V., primary, Lhuillier, A., additional, Bigot, C., additional, Pierard, L., additional, Trensz, P., additional, Schuster, C., additional, Malouf, G., additional, Fritsch, A., additional, Borchiellini, D., additional, Geoffrois, L., additional, and Barthelemy, P., additional

Published
2021
Full Text
View/download PDF

28. 713P Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial

Author

Naoun, N., primary, Le Teuff, G., additional, Pagliaro, L., additional, Fléchon, A., additional, Mardiak, J., additional, Geoffrois, L., additional, Kerbrat, P., additional, Chevreau, C.M., additional, Delva, R., additional, Rolland, F., additional, Theodore, C., additional, Roubaud, G., additional, Gravis, G., additional, Eymard, J-C., additional, Malhaire, J.P., additional, Linassier, C., additional, Reckova, M., additional, Nenan, S., additional, Culine, S., additional, and Fizazi, K., additional

Published
2021
Full Text
View/download PDF

29. Nephrectomy after complete response to immune checkpoint inhibitors for Metastatic Renal Cell Carcinoma (mRCC): A surgical challenge allowing favorable oncological outcomes

Author

Pignot, G., primary, Thiery-Vuillemin, A., additional, Walz, J., additional, Lang, H., additional, Balssa, L., additional, Geoffrois, L., additional, Leblanc, L., additional, Albiges, L., additional, Bensalah, K., additional, Ladoire, S., additional, Bigot, P., additional, Ingels, A., additional, Saldana, C., additional, Roubaud, G., additional, Piechaud, T., additional, Cassuto, O., additional, Klifa, D., additional, Parier, B., additional, Bernhard, J.C., additional, Malouf, G., additional, Gravis, G., additional, and Barthelemy, P., additional

Published
2021
Full Text
View/download PDF

30. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases

Author

Dahan, Laurie Saloner, primary, Giorgi, Roch, additional, Vergez, Sébastien, additional, Le Taillandier de Gabory, Ludovic, additional, Costes-Martineau, Valérie, additional, Herman, Philippe, additional, Poissonnet, Gilles, additional, Mauvais, Olivier, additional, Malard, Olivier, additional, Garrel, Renaud, additional, Uro-Coste, Emmanuelle, additional, Barry, Béatrix, additional, Bach, Christine, additional, Chevalier, Dominique, additional, Mouawad, Francois, additional, Merol, Jean-Claude, additional, Bastit, Vianney, additional, Thariat, Juliette, additional, Gilain, Laurent, additional, Dufour, Xavier, additional, Righini, Christian-Adrien, additional, Moya-Plana, Antoine, additional, Even, Caroline, additional, Radulesco, Thomas, additional, Michel, Justin, additional, Baujat, Bertrand, additional, Fakhry, Nicolas, additional, Albert, S., additional, Andry, G., additional, Babin, E., additional, Bach, C., additional, Badet, J.-M., additional, Badoual, C., additional, Baglin, A.C., additional, Banal, A., additional, Barry, B., additional, Baudin, E., additional, Baujat, B., additional, Bensadoun, R.J., additional, Bertolus, C., additional, Bessède, J.-P., additional, Blanchard, D., additional, Borel, C., additional, Bozorg-Grayeli, A., additional, Breheret, R., additional, Breton, P., additional, Brugel, L., additional, Calais, G., additional, Casiraghi, O., additional, Cassagnau, E., additional, Castillo, L., additional, Ceruse, P., additional, Chabolle, F., additional, Chevalier, D., additional, Chobaut, J.C., additional, Choussy, O., additional, Cosmidis, A., additional, Coste, A., additional, Costes, V., additional, Crampette, L., additional, Darrouzet, V., additional, Demez, P., additional, Dessi, P., additional, Devauchelle, B., additional, Dolivet, G., additional, Dubrulle, F., additional, Duflo, S., additional, Dufour, X., additional, Faivre, S., additional, Fakhry, N., additional, Ferron, C., additional, Floret, F., additional, de Gabory, L., additional, Garrel, R., additional, Geoffrois, L., additional, Gilain, L., additional, Giovanni, A., additional, Girod, A., additional, Guerrier, B., additional, Hans, S., additional, Herman, P., additional, Hofman, P., additional, Housset, M., additional, Jankowski, R., additional, Jegoux, F., additional, Juliéron, M., additional, Kaminsky, M.-C., additional, Kolb, F., additional, St Guily, J. Lacau, additional, Laccoureye, L., additional, Lallemant, B., additional, Lang, P., additional, Lartigau, E., additional, Lavieille, J.-P., additional, Lefevre, M., additional, Leroy, X., additional, Malard, O., additional, Massip, F., additional, Mauvais, O., additional, Merol, J.-C., additional, Michel, J., additional, Mom, T., additional, Morinière, S., additional, de Monès, E., additional, Moulin, G., additional, Noel, G., additional, Poissonnet, G., additional, Prades, J.-M., additional, Radulesco, T., additional, de Raucourt, D., additional, Reyt, E., additional, Righini, C., additional, Robin, Y. Marie, additional, Rolland, F., additional, Ruhin, B., additional, Sarroul, N., additional, Schultz, P., additional, Serrano, E., additional, Sterkers, O., additional, Strunski, V., additional, Sudaka, A., additional, Tassart, M., additional, Testelin, S., additional, Thariat, J., additional, Timochenko, A., additional, Toussaint, B., additional, Coste, E. Uro, additional, Valette, G., additional, Van den Abbeele, T., additional, Varoquaux, A., additional, Veillon, F., additional, Vergez, S., additional, and Wassef, M., additional

Published
2021
Full Text
View/download PDF

31. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author

Guigay, J, Auperin, A, Fayette, J, Saada-Bouzid, E, Lafond, C, Taberna, M, Geoffrois, L, Martin, L, Capitain, O, Cupissol, D, Castanie, H, Vansteene, D, Schafhausen, P, Johnson, A, Even, C, Sire, C, Duplomb, S, Evrard, C, Delord, JP, Laguerre, B, Zanetta, S, Chevassus-Clement, C, Fraslin, A, Louat, F, Sinigaglia, L, Keilholz, U, Bourhis, J, Mesia, R, Gallego, O, López Pousa A., and Vazquez Fernandez, Silvia

Abstract

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) showed promising results, with a median overall survival of 14.0 months in first-line recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). We therefore aimed to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen (platinum-fluorouracil-cetuximab) in this setting. Methods This was a multicentre, open-label, randomised, phase 2 trial, done in 68 centres (cancer centres, university and general hospitals, and private clinics) in France, Spain, and Germany. Eligible patients were aged 18-70 years with histologically confirmed recurrent or metastatic HNSCC unsuitable for curative treatment; had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Participants were randomly assigned (1:1) using the TenAlea website by investigators or delegated clinical research associates to the TPEx regimen or the EXTREME regimen, with minimisation by ECOG performance status, type of disease evolution, previous cetuximab treatment, and country. The TPEx regimen consisted of docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2), both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m(2) on day 1 of cycle 1 and 250 mg/m(2) weekly subsequently). Four cycles were repeated every 21 days with systematic granulocyte colony-stimulating factor (G-CSF) support at each cycle. In case of disease control after four cycles, intravenous cetuximab 500 mg/m(2) was continued every 2 weeks as maintenance therapy until progression or unacceptable toxicity. The EXTREME regimen consisted of fluorouracil 4000 mg/m(2) on day 1-4, cisplatin 100 mg/m(2) on day 1, and cetuximab on days 1, 8, and 15 (400 mg/m(2) on day 1 of cycle 1 and 250 mg/m(2) weekly subsequently) all delivered intravenously. Six cycles were delivered every 21 days followed by weekly 250 mg/m(2) cetuximab as maintenance therapy in case of disease control. G-CSF support was not mandatory per the protocol in the EXTREME regimen. The primary endpoint was overall survival in the intention-to-treat population; safety was analysed in all patients who received at least one dose of chemotherapy or cetuximab. Enrolment is closed and this is the final analysis. This study is registered at ClinicalTrials.gov, NCT02268695. Findings Between Oct 10, 2014, and Nov 29, 2017, 541 patients were enrolled and randomly assigned to the two treatment regimens (271 to TPEx, 270 to EXTREME). Two patients in the TPEx group had major deviations in consent forms and were not included in the final analysis. Median follow-up was 34.4 months (IQR 26.6-44.8) in the TPEx group and 30.2 months (25.5-45.3) in the EXTREME group. At data cutoff, 209 patients had died in the TPEx group and 218 had died in the EXTREME group. Overall survival did not differ significantly between the groups (median 14.5 months [95% CI 12.5-15.7] in the TPEx group and 13.4 months [12.2-15.4] in the EXTREME group; hazard ratio 0.89 [95% CI 0.74-1.08]; p=0.23). 214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p

Published
2021

32. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Author

Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. -J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., Robert, C., Eggermont, A. M. M., EORTC Melanoma Group, Lesimple, T., Maio, M., Linette, G., Mortier, L., Svane, I. M., Schachter, J., Brown, M., Hersey, P., Barrow, C., Kudchadkar, R., Dutriaux, C., Song, X., Quaglino, P., Queirolo, P., Meier, F., Stroyakovskiy, D., Guillot, B., Romero, P. L. O., Bastholt, L., Garbe, C., Grange, F., Mohr, P., Algazi, A., Bechter, O., Hernberg, M., Loquai, C., Meiss, F., Chiarion Sileni, V., Bar-Sela, G., Fitzharris, B., Saiag, P., Arnault, J. -P., Simon, J. -C., Stephens, R., Baurain, J. -F., Lebbe, C., Combemale, P., Dummer, R., Hauschild, A., Parente, P., Yamazaki, N., Milhem, M., Leccia, M. -T., Geoffrois, L., Kretschmer, L., Dunwoodie, E., Walker, J., Lotem, M., Hendler, D., Mackiewicz, A., Sekulovic, L., Dzienis, M., Hospers, G. A. P., Siano, M., Hassel, J., Corrie, P., Passos, M. -J., Levin, M., Hoeller, C., Machet, L., Hallmeyer, S., Waterston, A., Descamps, V., Kiecker, F., Aarts, M., Schmidt, H., Raimundo, A., Nyakas, M., Lacour, J. -P., Berking, C., Ferrucci, P. F., Jameson, M., Kim, K., Yokota, K., Kerger, J., Aubin, F., Groenewegen, G., Kapiteijn, H., Boehncke, W. -H., Utikal, J., Casasola, R., Marshall, E., Ferraresi, V., Richtig, E., Matkovic, S., Inozume, T., Crook, T., Mcneil, C., Kiyohara, Y., Avril, M. -F., Hein, R., Terheyden, P., Nathan, P., Aoi, J., Skytta, T., Jouary, T., Takenouchi, T., Straume, O., Martins, C., Mukhametshina, G., Boehncke, Wolf-Henning, Internal medicine, CCA - Cancer Treatment and quality of life, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Ospedale 'Santa Maria della Misericordia' = University Hospital 'Santa Maria della Misericordia', The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Edith Cowan University (ECU), Universitat de Barcelona (UB), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), Merck & Co. Inc, AP-HP. Université Paris Saclay, Institut Gustave Roussy (IGR), University Medical Center [Utrecht], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Merck Sharp & Dohme., and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, Skin Neoplasms, Medizin, Skin Neoplasms / drug therapy, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Melanoma / pathology, Randomized controlled trial, law, Monoclonal, 80 and over, Clinical endpoint, MESH: Double-Blind Method, 030212 general & internal medicine, Humanized, Melanoma, MESH: Aged, ddc:616, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Antibodies, Monoclonal, Humanized, Neoplasm Staging, Quality of Life, Double-Blind Method, Adult, Aged, Middle aged, Humans [MeSH], Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Humans, medicine.medical_specialty, Melanoma / psychology, Skin Neoplasms / psychology, MESH: Melanoma, Antibodies, Monoclonal, Humanized / therapeutic use, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, Melanoma / mortality, 03 medical and health sciences, Internal medicine, medicine, Adjuvant therapy, education, Skin Neoplasms / pathology, MESH: Humans, Melanoma / drug therapy, business.industry, MESH: Skin Neoplasms, MESH: Quality of Life, MESH: Adult, Skin Neoplasms / mortality, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
Abstract

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; pMethods: This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Patients aged 18 years or older with previously untreated histologically confirmed stage IIIA, IIIB, or IIIC resected cutaneous melanoma, and an Eastern Cooperative Oncology Group performance status score of 1 or 0 were eligible. Patients were randomly assigned (1:1) using a central interactive voice-response system on the basis of a minimisation technique stratified for stage and geographic region to receive intravenously 200 mg pembrolizumab or placebo. Treatment was administered every 3 weeks for 1 year, or until disease recurrence, unacceptable toxicity, or death. The primary endpoint of the trial was recurrence-free survival (reported elsewhere). HRQOL was a prespecified exploratory endpoint, with global health/quality of life (GHQ) over 2 years measured by the EORTC QLQ-C30 as the primary analysis. Analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-004944-37, and long-term follow-up is ongoing.Findings: Between Aug 26, 2015, and Nov 14, 2016, 1019 patients were assigned to pembrolizumab (n=514) or placebo (n=505). Median follow-up was 15·1 months (IQR 12·8-16·9) at the time of this analysis. HRQOL compliance was greater than 90% at baseline, greater than 70% during the first year, and greater than 60% thereafter for both groups. Because of low absolute compliance numbers at later follow-up, the analysis was truncated to week 84. Baseline GHQ scores were similar between groups (77·55 [SD 18·20] in the pembrolizumab group and 76·54 [17·81] in the placebo group) and remained stable over time. The difference in average GHQ score between the two groups over the 2 years was -2·2 points (95% CI -4·3 to -0·2). The difference in average score during treatment was -1·1 points (95% CI -3·2 to 0·9) and the difference in average score after treatment was -2·2 points (-4·8 to 0·4). These differences are within the 5-point clinical relevance threshold for the QLQ-C30 and are therefore clinically non-significant.Interpretation: Pembrolizumab does not result in a clinically significant decrease in HRQOL compared with placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting. placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting. placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting.

Published
2021

35. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Author

Grawis, G., Pignot, G., Flechon, A., Fendler, J.P., Chevreau, C., Soulie, M., Mahammedi, H., Guy, L., Laguerre, B., Verhoest, G., Guillot, A., Mottet, N., Joly, F., Doerfler, A., Abadie-Lacourtoisie, S., Azzouzi, A.R., Mongiat, P., Geoffrois, L., Eschwege, P., Di Fiore, F., Roubaud, G., Hoepffner, J.L., Barthelemy, P., Lang, H., Voog, E., Mandron, E., Tourani, J.M., Serrrate, C., Colau, A., Saldana, C., de La Taille, A., Nguyen, T., Kleinclauss, F., Loriot, Y., Irani, J., Eymard, J.C., Larre, S., Huillard, O., Zerbib, M., Rolland, F., Rigaud, J., Houede, N., Droupy, S., Malouf, G., Roupret, M., El Demery, M., Legon, C., Vieillot, S., Letang, N., Lharidon, T., Gaschignard, N., Hilgers, W., Davin, J.L., Pfister, Christian, Harter, Valentin, Allory, Yves, Radvanyi, François, and Culine, Stéphane

Published
2020
Full Text
View/download PDF

36. Chapitre 9: les autres modèles animaux alternatifs

Author

Tricoire, Hervé, Geoffrois, L, Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Institut National de l'Environnement Industriel et des Risques (INERIS)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

37. GETUG collaborative group. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma : Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Author

Negrier, S, Rioux-Leclercq, N, Ferlay, C, Gross-Goupil, M, Gravis, G, Geoffrois, L, Chevreau, C, Boyle, H, Rolland, F, Blanc, E, Ravaud, A, Dermeche, S, Flechon, A, Albiges, L, Pérol, D, Escudier, B, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

38. PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France

Author

Massetti, M., primary, Even, C., additional, Geoffrois, L., additional, Farge, G., additional, Levy Bachelot, L., additional, Borse, R., additional, Chirovsky, D., additional, and Durand-Zaleski, I., additional

Published
2020
Full Text
View/download PDF

40. 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial

Author

Courcier, J., primary, Dalban, C., additional, Laguerre, B., additional, Ladoire, S., additional, Barthélémy, P., additional, Oudard, S., additional, Joly, F., additional, Gravis Mescam, G., additional, Chevreau, C.M., additional, Geoffrois, L., additional, Deluche, E., additional, Rolland, F., additional, Topart, D., additional, Culine, S., additional, Négrier, S., additional, Mahammedi, H., additional, Tantot, F., additional, Escudier, B., additional, Flippot, R., additional, and Albiges, L., additional

Published
2020
Full Text
View/download PDF

41. 722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study

Author

Gross-Goupil, M., primary, Fléchon, A., additional, Mourey, L., additional, Topart, D., additional, Gravis, G., additional, Oudard, S., additional, Tourani, J.M., additional, Geoffrois, L., additional, Meriaux, E., additional, Thiery-Vuillemin, A., additional, Barthélémy, P., additional, Ladoire, S., additional, Laguerre, B., additional, Bourouina, R., additional, Perrot, V., additional, Escudier, B., additional, and Albiges, L., additional

Published
2020
Full Text
View/download PDF

42. 732P Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study

Author

Fléchon, A., primary, Chevreau, C.M., additional, Topart, D., additional, Gravis, G., additional, Oudard, S., additional, Tourani, J.M., additional, Geoffrois, L., additional, Meriaux, E., additional, Thiery-Vuillemin, A., additional, Barthélémy, P., additional, Ladoire, S., additional, Laguerre, B., additional, Bourouina, R., additional, Perrot, V., additional, Escudier, B., additional, Gross-Goupil, M., additional, and Albiges, L., additional

Published
2020
Full Text
View/download PDF

43. 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations

Author

Siefker-Radtke, A.O., primary, Loriot, Y., additional, Siena, S., additional, Beato, C., additional, Duran, M.A. Climent, additional, Varlamov, S., additional, Duran, I., additional, Tagawa, S.T., additional, Geoffrois, L., additional, Mellado, B., additional, Semenov, A., additional, Delva, R., additional, Lykov, A.P., additional, Dirix, L.Y., additional, Akapame, S., additional, O'Hagan, A., additional, Tammaro, M., additional, Mosher, S., additional, Kang, T.W., additional, and Moreno, V., additional

Published
2020
Full Text
View/download PDF

44. 1878P Health-related quality of life (HRQoL) assessment for patients with advanced renal cell carcinoma (aRCC) treated with a tyrosine kinase inhibitor (TKI) using electronic patient reported outcomes in daily clinical practice: QUANARIE trial

Author

Mouillet, G., primary, Falcoz, A., additional, Barthélémy, P., additional, Geoffrois, L., additional, Ladoire, S., additional, Eymard, J-C., additional, Plaza, J., additional, Viel, E., additional, Maurina, T., additional, Calcagno, F., additional, Stein, U., additional, Fritzsch, J., additional, Djoumakh, O., additional, Paget-Bailly, S., additional, and Thiery-Vuillemin, A., additional

Published
2020
Full Text
View/download PDF

45. LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial

Author

Bourhis, J., primary, Sire, C., additional, Tao, Y., additional, Martin, L., additional, Alfonsi, M., additional, Prevost, J.B., additional, Rives, M., additional, Lafond, C., additional, Tourani, J.M., additional, Biau, J., additional, Geoffrois, L., additional, Coutte, A., additional, Liem, X., additional, Vauleon, E., additional, Drouet, F., additional, Pechery, A., additional, Guigay, J., additional, Wanneveich, M., additional, Aupérin, A., additional, and Sun, X., additional

Published
2020
Full Text
View/download PDF

47. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic Renal Cell Carcinoma (mRCC): A new surgical challenge?

Author

Pignot, G., primary, Thiery-Vuillemin, A., additional, Walz, J., additional, Lang, H., additional, Werle, P., additional, Balssa, L., additional, Geoffrois, L., additional, Leblanc, L., additional, Albigès, L., additional, Di Nunno, V., additional, Bensalah, K., additional, Ladoire, S., additional, Gravis, G., additional, and Barthélémy, P., additional

Published
2020
Full Text
View/download PDF

48. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Author

Pfister, Christian, primary, Harter, Valentin, additional, Allory, Yves, additional, Radvanyi, François, additional, Culine, Stéphane, additional, Grawis, G., additional, Pignot, G., additional, Flechon, A., additional, Fendler, J.P., additional, Chevreau, C., additional, Soulie, M., additional, Mahammedi, H., additional, Guy, L., additional, Laguerre, B., additional, Verhoest, G., additional, Guillot, A., additional, Mottet, N., additional, Joly, F., additional, Doerfler, A., additional, Abadie-Lacourtoisie, S., additional, Azzouzi, A.R., additional, Mongiat, P., additional, Geoffrois, L., additional, Eschwege, P., additional, Di Fiore, F., additional, Roubaud, G., additional, Hoepffner, J.L., additional, Barthelemy, P., additional, Lang, H., additional, Voog, E., additional, Mandron, E., additional, Tourani, J.M., additional, Serrrate, C., additional, Colau, A., additional, Saldana, C., additional, de La Taille, A., additional, Nguyen, T., additional, Kleinclauss, F., additional, Loriot, Y., additional, Irani, J., additional, Eymard, J.C., additional, Larre, S., additional, Huillard, O., additional, Zerbib, M., additional, Rolland, F., additional, Rigaud, J., additional, Houede, N., additional, Droupy, S., additional, Malouf, G., additional, Roupret, M., additional, El Demery, M., additional, Legon, C., additional, Vieillot, S., additional, Letang, N., additional, Lharidon, T., additional, Gaschignard, N., additional, Hilgers, W., additional, and Davin, J.L., additional

Published
2020
Full Text
View/download PDF

50. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France

Author

Moya-Plana, A., primary, Aupérin, A., additional, Obongo, R., additional, Baglin, A., additional, Ferrand, F.R., additional, Baujat, B., additional, Saroul, N., additional, Casiraghi, O., additional, Vergez, S., additional, Herman, P., additional, Janot, F., additional, Thariat, J., additional, Vérillaud, B., additional, de Gabory, L., additional, Albert, S., additional, Andry, G., additional, Babin, E., additional, Bach, C., additional, Badet, J.-M., additional, Badoual, C., additional, Baglin, A.C., additional, Banal, A., additional, Barry, B., additional, Baudin, E., additional, Bensadoun, R.J., additional, Bertolus, C., additional, Bessède, J.-P., additional, Blanchard, D., additional, Borel, C., additional, Bozorg-Grayeli, A., additional, Breheret, R., additional, Breton, P., additional, Brugel, L., additional, Calais, G., additional, Cassagnau, E., additional, Castillo, L., additional, Ceruse, P., additional, Chabolle, F., additional, Chevalier, D., additional, Chobaut, J.C., additional, Choussy, O., additional, Cosmidis, A., additional, Coste, A., additional, Costes, V., additional, Crampette, L., additional, Darrouzet, V., additional, Demez, P., additional, Dessi, P., additional, Devauchelle, B., additional, Digue, L., additional, Dolivet, G., additional, Dubrulle, F., additional, Duflo, S., additional, Dufour, X., additional, Even, C., additional, Faivre, S., additional, Fakhry, N., additional, Ferron, C., additional, Floret, F., additional, Garrel, R., additional, Geoffrois, L., additional, Gilain, L., additional, Giovanni, A., additional, Girod, A., additional, Guerrier, B., additional, Hans, S., additional, Hofman, P., additional, Housset, M., additional, Jankowski, R., additional, Jegoux, F., additional, Juliéron, M., additional, Kaminsky, M.-C., additional, Kolb, F., additional, Lacau St Guily, J., additional, Laccoureye, L., additional, Lallemant, B., additional, Lang, P., additional, Lartigau, E., additional, Lavieille, J.-P., additional, Lefevre, M., additional, Leroy, X., additional, Malard, O., additional, Massip, F., additional, Mauvais, O., additional, Merol, J.-C., additional, Michel, J., additional, Mom, T., additional, Morinière, S., additional, de Monès, E., additional, Moulin, G., additional, Moya-Plana, A., additional, Noel, G., additional, Poissonnet, G., additional, Prades, J.-M., additional, de Raucourt, D., additional, Reyt, E., additional, Righini, C., additional, Marie Robin, Y., additional, Rolland, F., additional, Ruhin, B., additional, Sarroul, N., additional, Schultz, P., additional, Serrano, E., additional, Sterkers, O., additional, Strunski, V., additional, Sudaka, A., additional, Tassart, M., additional, Testelin, S., additional, Timochenko, A., additional, Toussaint, B., additional, Uro Coste, E., additional, Valette, G., additional, Van den Abbeele, T., additional, Varoquaux, A., additional, Veillon, F., additional, and Wassef, M., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results